Saltar al contenido
PivotalWire
Domingo 11 oct 2026SEC · NASDAQ biomédico

Portada›Jueves 18 de diciembre de 2025

Biomédicas del NASDAQ ante la SEC, jueves 18 de diciembre de 2025

Los 46 documentos que 35 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. CAMPCamp4 Therapeutics Corp424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon (which includes an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern described in Note 1 to the consolidated financial statements), included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance…
  2. CUECue Biopharma, Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…believe our Immuno-STAT platform holds the promise of producing drug product candidates with the potential of establishing new standards of care in the treatment of autoimmune disease. Events that Raise Substantial Doubt About Our Ability to Continue as a Going Concern We will need to raise substantial additional capital to fund our operations and remain as a going concern. As of September 30, 2025, we had $18.7 million in cash, cash equivalents and marketable securities…
  3. KYTXKyverna Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
  4. LYELLyell Immunopharma, Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoContrasplit de accionestexto original ▸…investors are cautioned not to unduly rely upon these statements. 7 Table of Contents SELECTED FINANCIAL DATA REFLECTING REVERSE STOCK SPLIT Reverse Stock Split At 5:00 p.m. Eastern Time on May 30, 2025, we effected a 1-for-20 reverse stock split of our common stock (the “Reverse Stock Split”). Based on such Reverse Stock Split, the total number of outstanding shares of common stock was adjusted from 296,161,570 shares to approximately 14,808…
  5. BCRXBIOCRYST PHARMACEUTICALS INC424B3Prospecto suplementario o de reventaEDGAR
  6. BDRXBiodexa Pharmaceuticals Plc424B3Prospecto suplementario o de reventaEDGAR
  7. BDRXBiodexa Pharmaceuticals Plc424B3Prospecto suplementario o de reventaEDGAR
  8. BDRXBiodexa Pharmaceuticals Plc424B3Prospecto suplementario o de reventaEDGAR
  9. BDRXBiodexa Pharmaceuticals Plc424B3Prospecto suplementario o de reventaEDGAR
  10. BDRXBiodexa Pharmaceuticals Plc424B3Prospecto suplementario o de reventaEDGAR
  11. CGTXCOGNITION THERAPEUTICS INCS-3Capacidad de emisión registradaEDGAR
  12. FBIOFortress Biotech, Inc.424B3Prospecto suplementario o de reventaEDGAR
  13. IMAImageneBio, Inc.424B3Prospecto suplementario o de reventaEDGAR

Participaciones y control

  1. VORVor Biopharma Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. CGTXCOGNITION THERAPEUTICS INC8-KFin de acuerdo materialEDGAR
  2. KLRSKalaris Therapeutics, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
  3. LONALeonaBio, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
    En el documentoDesignación de vía rápida (Fast Track)texto original ▸…lasofoxifene for the treatment of men or women with locally advanced or metastatic estrogen receptor-positive (ER+) breast cancer with an ESR1 mutation (ELAINE-1 and ELAINE-2 studies). In May 2019, the FDA granted lasofoxifene Fast Track Designation. A pivotal Phase 3 trial (ELAINE-3) is underway with topline data expected in 2027. In December 2025, Athira in-licensed lasofoxifene globally, excluding Asia and certain countries in the Middle East…
  4. LONALeonaBio, Inc.8-K/AVenta de acciones no registrada (colocación privada)EDGAR
    En el documentoDesignación de vía rápida (Fast Track)texto original ▸…lasofoxifene for the treatment of men or women with locally advanced or metastatic estrogen receptor-positive (ER+) breast cancer with an ESR1 mutation (ELAINE-1 and ELAINE-2 studies). In May 2019, the FDA granted lasofoxifene Fast Track Designation. A pivotal Phase 3 trial (ELAINE-3) is underway with topline data expected in 2027. In December 2025, Athira in-licensed lasofoxifene globally, excluding Asia and certain countries in the Middle East…
  5. NEUPNeuphoria Therapeutics Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
  6. VORVor Biopharma Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
  7. CAMPCamp4 Therapeutics Corp8-KNuevo acuerdo materialEDGAR
  8. CAMPCamp4 Therapeutics Corp8-KNuevo acuerdo materialEDGAR
  9. CRBPCorbus Pharmaceuticals Holdings, Inc.8-KCambio en el consejo o la direcciónEDGAR
  10. DMACDiaMedica Therapeutics Inc.8-KOtros hechos relevantesEDGAR
  11. FLNAFILANA THERAPEUTICS, INC.8-KOtros hechos relevantesEDGAR
  12. GANXGain Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
  13. HOWLWerewolf Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
  14. IMAImageneBio, Inc.8-KCambio en el consejo o la direcciónEDGAR
  15. INDVIndivior Pharmaceuticals, Inc.8-KCambio en el consejo o la direcciónEDGAR
  16. IXHLIncannex Healthcare Inc.8-KOtros hechos relevantesEDGAR
  17. KODKodiak Sciences Inc.8-KOtros hechos relevantesEDGAR
  18. KRROKorro Bio, Inc.8-KCambio en el consejo o la direcciónEDGAR
  19. KYTXKyverna Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
  20. OCGNOcugen, Inc.8-KCambio en el consejo o la direcciónEDGAR
  21. OCULOCULAR THERAPEUTIX, INC8-KOtros hechos relevantesEDGAR
  22. ONCBeOne Medicines Ltd.8-KCambio en el consejo o la direcciónEDGAR
  23. OVIDOvid Therapeutics Inc.8-KOtros hechos relevantesEDGAR
  24. PAHCPHIBRO ANIMAL HEALTH CORP8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸…tm2533792d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For Immediate Release Phibro Animal Health Corporation Announces Leadership Transition - Jack Bendheim to assume the role of Executive Chairman; Daniel Bendheim named Chief Executive Officer and President TEANECK, N.J. December 18, 2025 (Business Wire) --Phibro Animal Health Corporation (Nasdaq: PAHC) (the “Company” or “Phibro”) today announced a leadership transition that will support the…
  25. PMCBPharmaCyte Biotech, Inc.10-QInforme trimestralEDGAR
  26. PULMPulmatrix, Inc.8-KOtros hechos relevantesEDGAR
  27. PYXSPyxis Oncology, Inc.8-KOtros hechos relevantesEDGAR
    En el documentoDesignación de vía rápida (Fast Track)texto original ▸…pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extra-cellular matrix density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD(L)-1 therapy…
  28. RNACCartesian Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
  29. SGMTSagimet Biosciences Inc.8-KOtros hechos relevantesEDGAR
  30. TVRDTvardi Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
  31. VERAVera Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR

Juntas de accionistas

  1. FBLGFibroBiologics, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
    En el documentoContrasplit de accionestexto original ▸…Company and our stockholders and is likely to improve the trading price of our Common Stock and improve the likelihood that we will be allowed to maintain our listing on Nasdaq. Accordingly, our Board approved the Reverse Stock Split Amendment as being in the best interests of the Company. Risks Associated with the Reverse Stock Split The Reverse Stock Split May Not Increase the Price of our Common Stock over the Long-Term and our…

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.